Development and Performance Evaluation of Amphotericin B Transfersomes Against Resistant and Sensitive Clinical Isolates of Visceral Leishmaniasis

被引:23
作者
Singodia, D. [1 ]
Gupta, G. K. [1 ]
Verma, A. [1 ]
Singh, V. [1 ]
Shukla, P. [1 ]
Misra, P. [2 ]
Sundar, S. [3 ]
Dube, A. [2 ]
Mishra, P. R. [1 ]
机构
[1] Cent Drug Res Inst, Div Pharmaceut, Lucknow 226001, Uttar Pradesh, India
[2] Cent Drug Res Inst, Div Parasitol, Lucknow 226001, Uttar Pradesh, India
[3] Inst Med Sci, Dept Med, Bhu Varanasi 221005, India
关键词
Transfersomes; Amphotericin B; Visceral Leishmaniasis; Surfactant; Transdermal delivery; PENTAVALENT ANTIMONY; TRANSDERMAL DELIVERY; LIPID FORMULATIONS; DRUG; DONOVANI; RELEASE; IMPACT;
D O I
10.1166/jbn.2010.1121
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The present study was aimed to assess the efficacy of developed transfersome (TF-3) formulation bearing amphotericin B (AmB) against sensitive and resistant clinical isolates of L donovani and compared with conventional liposomal formulation (F-2) and free AmB (F-1). The skin permeation of AmB from TF-3 was performed using Franz diffusion cell using rat skin which showed fickian diffusion across the skin. When tested against L. donovani (intramacrophagic amastigotes), it has been observed that TF was more effective than F-1 and F-2 formulation in sensitive and resistant clinical isolates. The data provides evidences that the TF formulation owing to its fluidized behaviour imparted by sodium deoxycholate, enables to penetrate well in the infected cells and thus provide enhanced activity. The permeation study also supports this data as the flux value of AmB through TF formulation was 1.5 fold higher compared to conventional liposomes suggesting improved penetration and better partitioning in skin layers. Implicit to this preliminary data it is evident that the AmB loaded TF formulation has potential as alternate chemotherapeutic approach to control of VL. Potential utilities of novel formulation as a transdermal delivery of AmB for leishmaniasis necessitates further elaborated investigations which is underway in our laboratory.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 33 条
[1]   Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana [J].
Al-Mohammed, HI ;
Chance, ML ;
Bates, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3274-3280
[2]   Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection [J].
Basu, Jayati Mookerjee ;
Mookerjee, Ananda ;
Banerjee, Rajdeep ;
Saha, Manik ;
Singh, Subhankar ;
Naskar, Ksudiram ;
Tripathy, Gayetri ;
Sinha, Prabhat K. ;
Pandey, Krishna ;
Sundar, Shyam ;
Bimal, Sanjeev ;
Das, Pradip K. ;
Choudhuri, Sournitra K. ;
Roy, Syarnal .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (03) :1080-1093
[4]   US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis - Editorial response [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :49-51
[5]   Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo [J].
Cevc, G ;
Blume, G ;
Schatzlein, A .
JOURNAL OF CONTROLLED RELEASE, 1997, 45 (03) :211-226
[6]  
CLEMENTS JS, 1990, AM J MED, V88, pN22
[7]   Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery [J].
Ferderber, Kristina ;
Hook, Sarah ;
Rades, Thomas .
JOURNAL OF LIPOSOME RESEARCH, 2009, 19 (04) :267-277
[8]  
Garg T, 2008, DRUG DEV IND PHARM, V34, P1100, DOI [10.1080/03639040801965079, 10.1080/03639040801965079 ]
[9]   Development of liposomal amphotericin B formulation [J].
Gulati, M ;
Bajad, S ;
Singh, S ;
Ferdous, AJ ;
Singh, M .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (02) :137-151
[10]   Amphotericin B: New life for an old drug [J].
Hartsel, S ;
Bolard, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (12) :445-449